Literature DB >> 18391918

Erlotinib-induced acute hepatitis in a patient with pancreatic cancer.

Muhammad Wasif Saif1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 18391918

Source DB:  PubMed          Journal:  Clin Adv Hematol Oncol        ISSN： 1543-0790


× No keyword cloud information.
  6 in total

1.  Cytochrome P450-mediated bioactivation of the epidermal growth factor receptor inhibitor erlotinib to a reactive electrophile.

Authors:  Xiaohai Li; Theodore M Kamenecka; Michael D Cameron
Journal:  Drug Metab Dispos       Date:  2010-04-09       Impact factor: 3.922

Review 2.  Metabolism considerations for kinase inhibitors in cancer treatment.

Authors:  Derek R Duckett; Michael D Cameron
Journal:  Expert Opin Drug Metab Toxicol       Date:  2010-10       Impact factor: 4.481

3.  Reactivation of hepatitis B virus after withdrawal of erlotinib.

Authors:  N Bui; I Wong-Sefidan
Journal:  Curr Oncol       Date:  2015-12       Impact factor: 3.677

Review 4.  Hepatotoxicity of tyrosine kinase inhibitors: clinical and regulatory perspectives.

Authors:  Rashmi R Shah; Joel Morganroth; Devron R Shah
Journal:  Drug Saf       Date:  2013-07       Impact factor: 5.606

5.  Acute Fatal Liver Toxicity under Erlotinib.

Authors:  Sabina Schacher-Kaufmann; Miklos Pless
Journal:  Case Rep Oncol       Date:  2010-06-08

6.  Disposition of Erlotinib and Its Metabolite OSI420 in a Patient with High Bilirubin Levels.

Authors:  M Czejka; A Sahmanovic; P Buchner; T Steininger; C Dittrich
Journal:  Case Rep Oncol       Date:  2013-12-12
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.